Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27kip1 by PKB/Akt-mediated phosphorylation in breast cancer

Nature Medicine

Volumn 8, Issue 10, 2002, Pages 1136-1144

  Viglietto, Giuseppe ^a   Motti, Maria Letizia ^a   Bruni, Paola ^b   Melillo, Rosa Marina ^a   D’alessio, Amelia ^c   Califano, Daniela ^c   Vinci, Floriana ^d   Chiappetta, Gennaro ^c   Tsichliss, Philip ^e   Bellacosa, Alfonso ^f,g   Fusco, Alfredo ^a   Santoro, Massimo ^a  

^a CNR   (Italy)

^b Dipartimento di Biochimica e Biotecnologie Mediche   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; THREONINE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENZYME REGULATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; THREONINE; TUMOR SUPPRESSOR PROTEINS;

EID: 18644370396     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm762     Document Type: Article

References (44)

1. Morgan, D.O. Principles of Cdk regulation. Nature 374, 131-134 (1995).
2. Sherr, C.J. & Roberts, J.M. CDK inhibitors: Positive and negative regulators of G1phase progression. Genes Dev. 13, 1501-1512 (1999).
3. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
4. Sherr, C.J. Cancer cell cycles. Science 274, 1672-1677 (1996).
5. Hunter, T. & Pines, J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79, 573-582 (1994).
6. Weinstat-Saslow, D. et al. cverexpression of cyelin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med. 1, 1257-1260 (1995).
7. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222-225 (1997).
8. Baldassarre, B. et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Invest. 10, 865-874 (1999).
9. Rocco J.W. & Sidransky, D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 264, 42-S5 (2001).
10. Otsuki, T., Clark, H.M., Wellmann, A., Jaffe, E.S. & Raffeld, M. Involvement of CDKN2 p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 55, 1436-1440 (1995).
11. kip1 and its alterations in tumor cells: A review. J. Cell Physiol. 183, 18-27 (2000).
12. kip1 is haplo-insufficient for tumor suppression. Nature 396, 177-180 (1998).
13. kip1 protein: Prognostic implications in primary breast cancer. Nature Med. 3, 227-230 (1997).
14. kip1 expression in endocrine and other tumors. Am. J. Pathol. 150, 401-407 (1997).
15. kip1 in aggressive colorectal carcinomas. Nature Med. 3, 231-234 (1997).
16. kip1 in multistage colorectal carcinogenesis. Cancer Res. 58, 114-122 (1998).
17. kip1 in Barrett's associated adenocarcinoma. Cancer Res. 58, 1730-1735 (1998).
18. kip1, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc. Natl. Acad. Sci. USA 97, 10538-10543 (2000).
19. kip1 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. USA 95, 15653-15658 (1998).
20. Orend, G., Hunter, T. & Ruoslahti, E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21 and p27 in anchorage-independent cells. Oncogene 16, 2575-2583 (1998).
21. Yaroslavskiy, B., Watkins, S., Donnenberg, A.D., Patton, T.J. & Steinman, R.A. Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells. Blood 93, 2907-2917 (1999).
22. kip1 is instigated by Jab1. Nature 398, 160-165 (1999).
23. Testa, J.R. & Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10983-10985 (2001).
24. Datta, S.R., Brunet, A. & Greenberg, M.E. Cellular survival: A play in three Akts. Genes Dev. 13, 2905-2927 (1999).
25. Datta, S.R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997).
26. Cardone, M.H. et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321 (1998).
27. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
28. Kops, G.J. et al. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630-634 (1999).
29. Zhou, B.P. et al. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol. 3, 245-252 (2001).
30. Coffer, P.J., Jin, J. & Woodgett, J.R. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335, 1-12 (1998).
31. Di Cristofano, A. & Pandolfi, P.P. The multiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000).
32. Lobenhofer, E.K., Huper, G., Iglehart, J.D. & Marks, J.R. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 11, 99-110 (2000).
33. Tsai, E.M., Wang, S.C., Lee, J.N. & Hung, M.C. Akt Activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res. 61, 8390-8392 (2001).
34. Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res. 61, 6583-6591 (2001).
35. Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. Oncogene 20, 3695-3702 (2001).
36. Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol. 10, 262-267 (1998).
37. Sun, M. et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159, 431-437 (2001).
38. Diehl, J.A., Cheng, M., Roussel, M.F. & Sherr, C.J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
39. Alt, J.R., Cleveland, J.L., Hannink, M. & Diehl, J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev., 14, 3102-3114 (2000).
40. Kip1 mislocalization. Oncogene 19, 5926-5935 (2000).
41. Bellacosa, A. et al. Akt activation by growth factors is a multiple-step process: The role of the PH domain. Oncogene 17, 313-325 (1998).
42. kip1 for embryonal carcinoma cell survival and differentiation. Oncogene 18, 6241-6251 (1999).
43. kip1. Oncogene 19, 3146-3155 (2000).
44. Kip1 a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).